- Home
- REX vs ORGO Comparison
REX vs ORGO Comparison
Compare REX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- ORGO
- Stock Information
- Founded
- REX 1980
- ORGO 1985
- Country
- REX United States
- ORGO United States
- Employees
- REX N/A
- ORGO N/A
- Industry
- REX Major Chemicals
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- ORGO Health Care
- Exchange
- REX Nasdaq
- ORGO Nasdaq
- Market Cap
- REX N/A
- ORGO 533.9M
- IPO Year
- REX N/A
- ORGO N/A
- Fundamental
- Price
- REX $40.83
- ORGO $3.05
- Analyst Decision
- REX Strong Buy
- ORGO Buy
- Analyst Count
- REX 1
- ORGO 2
- Target Price
- REX $50.00
- ORGO $5.50
- AVG Volume (30 Days)
- REX 124.0K
- ORGO 1.7M
- Earning Date
- REX 05-21-2025
- ORGO 05-08-2025
- Dividend Yield
- REX N/A
- ORGO N/A
- EPS Growth
- REX N/A
- ORGO N/A
- EPS
- REX 3.30
- ORGO N/A
- Revenue
- REX $642,491,000.00
- ORGO $482,043,000.00
- Revenue This Year
- REX $3.27
- ORGO $3.31
- Revenue Next Year
- REX $17.11
- ORGO $12.50
- P/E Ratio
- REX $11.92
- ORGO N/A
- Revenue Growth
- REX N/A
- ORGO 11.29
- 52 Week Low
- REX $33.45
- ORGO $2.17
- 52 Week High
- REX $60.41
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- REX 56.71
- ORGO 37.36
- Support Level
- REX $39.10
- ORGO $5.14
- Resistance Level
- REX $40.69
- ORGO $5.55
- Average True Range (ATR)
- REX 0.91
- ORGO 0.31
- MACD
- REX -0.05
- ORGO -0.01
- Stochastic Oscillator
- REX 55.47
- ORGO 0.30
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.